

**I. IN THE CLAIMS:**

This listing of claims below will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-8. (canceled)

9. (currently amended): An isolated monoclonal antibody against a peptide consisting of amino acid residues 375-580 of GPC 3 as set forth in SEQ ID NO: 4 which is not expressed in normal liver, wherein the antibody has ADCC or CDC activity in vitro against the cell line HepG2 in the presence of complement or peripheral blood mononuclear cells.

10-24. (canceled)

25. (previously presented): The antibody claimed in claim 9 which is a recombinant antibody.

26. (previously presented): The antibody claimed in claim 25, which is a humanized antibody.

27. (previously presented): The humanized antibody claimed in claim 26, wherein the V region is obtained from an antibody of a mammal except human and the C region is a C region of a human antibody.

28. (previously presented): The humanized antibody claimed in claim 27, wherein the C region of the H chain is selected from the group consisting of C $\gamma$ 1, C $\gamma$ 2, C $\gamma$ 3 and C $\gamma$ 4.

29. (previously presented): The humanized antibody claimed in claim 27, wherein the C region of the L chain is C $\kappa$  or C $\lambda$ .

30. (currently amended) The antibody in claim 9, wherein the antibody is humanized and wherein the antibody comprises comprising the CDR1, CDR2 and CDR3 of the H chain variable region as set forth in SEQ ID NO: 10 and the CDR1, CDR2 and CDR3 of the L chain variable region as set forth in SEQ ID NO: 18.

31. (previously presented) The antibody claimed in claim 30 which is a recombinant antibody.

32. (previously presented) The antibody claimed in claim 31, which is a humanized antibody.

33. (currently amended) The humanized antibody claimed in claim 32, wherein the V region is obtained from an antibody of a mouse mammal except human and the C region is a C region of a human antibody.

34. (previously presented) The humanized antibody claimed in claim 32, wherein the C region of the H chain is selected from the group consisting of C $\gamma$ 1, C $\gamma$ 2, C $\gamma$ 3 and C $\gamma$ 4.

35. (previously presented) The humanized antibody claimed in claim 32, wherein the C region of the L chain is C $\kappa$  or C $\lambda$ .

36. (currently amended) The antibody in claim 9, wherein the antibody is humanized and wherein the antibody comprises comprising the CDR1, CDR2 and CDR3 of the H chain variable region as set forth in SEQ ID NO: 12 and the CDR1, CDR2 and CDR3 of the L chain variable region as set forth in SEQ ID NO: 20.

37. (previously presented) The antibody claimed in claim 36 which is a recombinant antibody.

38. (previously presented) The antibody claimed in claim 37, which is a humanized antibody.

39. (currently amended) The humanized antibody claimed in claim 38, wherein the V region is obtained from an antibody of a mouse mammal-except human except human and the C region is a C region of a human antibody.

40. (previously presented) The humanized antibody claimed in claim 39, wherein the C region of the H chain is selected from the group consisting of C $\gamma$ 1, C $\gamma$ 2, C $\gamma$ 3 and C $\gamma$ 4.

41. (previously presented) The humanized antibody claimed in claim 39, wherein the C region of the L chain is C $\kappa$  or C $\lambda$ .

42. (new) The isolated monoclonal antibody of claim 1, wherein the mRNA expression of the peptide is higher in hepatoma lesions than the mRNA expression of the peptide in normal liver tissue and wherein the isolated monoclonal antibody detects cancer when exposed to cancer cells.

43. (new) The isolated monoclonal antibody of claim 1, wherein the mRNA expression of the peptide is higher in hepatoma lesions than the mRNA expression of the peptide in normal liver tissue and wherein the isolated monoclonal antibody is used in the treatment of cancer.

44. (new) The antibody in claim 9, wherein the antibody is chimeric and wherein the antibody comprises the CDR1, CDR2 and CDR3 of the H chain variable region as set forth in SEQ ID NO: 10 and the CDR1, CDR2 and CDR3 of the L chain variable region as set forth in SEQ ID NO: 18.

45. (new) The antibody in claim 9, wherein the antibody is chimeric and wherein the antibody comprises the CDR1, CDR2 and CDR3 of the H chain variable region as set forth in SEQ ID NO: 12 and the CDR1, CDR2 and CDR3 of the L chain variable region as set forth in SEQ ID NO: 20.